Pier Capital’s NovoCure NVCR Stock Holding History

Pier Capital’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-85,074	Closed	-$4.46M	–	121
2018 Q3	$4.46M	Sell	85,074 -177,787	-68%	-$7.08M	0.56%	92
2018 Q2	$8.23M	Sell	262,861 -83,489	-24%	-$2.32M	1.13%	20
2018 Q1	$7.55M	Sell	346,350 -39,177	-10%	-$843K	1.29%	11
2017 Q4	$7.79M	Buy	385,527 +112,176	+41%	+$2.16M	1.33%	7
2017 Q3	$5.43M	Buy	+273,351	New	+$5.37M	0.94%	75

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

DCP

Darsana Capital Partners New York $4.7B AUM 50.56% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Pier Capital's NVCR Position: Q4 2018 in Review

Pier Capital sold out of NovoCure (NVCR) in Q4 2018, closing a stake of 85,074 shares — an estimated $4.46M sold.

Pier Capital first reported a position in NVCR in Q3 2017 and held it in 5 quarters. The position peaked at $8.23M in Q2 2018. 166 funds tracked by Wall St. Rank hold NVCR as of Q4 2018.

Pier Capital reported no remaining NovoCure position as of Q4 2018 after selling out during the quarter.
Pier Capital sold 85,074 NovoCure shares in Q4 2018, an estimated $4.46M.
Pier Capital first reported a position in NovoCure in Q3 2017 and held it in 5 quarters.
Pier Capital's NovoCure position peaked at $8.23M in Q2 2018.
166 funds tracked by Wall St. Rank held NovoCure as of Q4 2018.

Based on Pier Capital's 13F filing for Q4 2018, filed 13 Feb 2019.